Anti-CD46 antibody drug conjugate (Fortis Therapeutics)

N/A

Report date: 2026/02/12 20:00:14
First In Class

Base Information

Drug NameAnti-CD46 antibody drug conjugate (Fortis Therapeutics)
Drug Alias NameAnti-CD46 antibody conjugate (Fortis Therapeutics)FOR-46FG-3246
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionAnti-MCPTubulin polymerisation inhibitors
TargetsMembrane cofactor proteinTubulin
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesFibrogen IncFortis Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A